GLP-1 Injection Peptides Semaglutide 5mg 10mg In Stock

GLP-1 Injection Peptides Semaglutide 5mg 10mg In Stock

has been approved for marketing in the United States to improve the blood sugar control of adult type 2 diabetes patients (based on diet control and exercise), and has been approved in the EU, Japan and other countries. According to the disclosed financial report data, the sales of (diabetes indication) in the first half of this year reached 1.548 billion US dollars, ranking 50th in the global top 100 list of drug sales.
In terms of weight loss indications, in October 2022, the FDA granted to improve long-term weight management in overweight adults with obesity or at least one comorbidities (based on a low calorie diet and increased physical activity)

is the first and currently the only glucose dependent insulin stimulating peptide (GIP) and glucagon like peptide-1 (GLP-1) receptor agonist (GIP/GLP-1 receptor agonist)